Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 44 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 12 | 22 | 4 | 4 |
| Last 30D | 0 | 0 | 0 | 0 | 1 |
| 1M Ago | 0 | 2 | 8 | 3 | 1 |
| 2M Ago | 2 | 7 | 11 | 1 | 1 |
| 3M Ago | 0 | 3 | 3 | 0 | 1 |
Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $26.66, accompanied by a high estimate of $65.00 and a low estimate of $5.00. A 31.5% drop is evident in the current average compared to the previous average price target of $38.92.
Understanding Analyst Ratings: A Comprehensive Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Sarepta Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mitchell S. Kapoor | HC Wainwright & Co. | Maintains | Sell | $5.00 | $5.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Underperform | $16.00 | $17.00 |
| Tazeen Ahmad | B of A Securities | Raises | Underperform | $17.00 | $10.00 |
| David Hoang | Deutsche Bank | Raises | Sell | $12.00 | $6.00 |
| Salveen Richter | Goldman Sachs | Raises | Neutral | $19.00 | $10.00 |
| Yanan Zhu | Wells Fargo | Raises | Overweight | $50.00 | $48.00 |
| Gena Wang | Barclays | Raises | Equal-Weight | $22.00 | $10.00 |
| Gena Wang | Barclays | Raises | Equal-Weight | $22.00 | $10.00 |
| Biren Amin | Piper Sandler | Raises | Neutral | $15.00 | $11.00 |
| William Pickering | Bernstein | Announces | Market Perform | $13.00 | - |
| Kostas Biliouris | BMO Capital | Raises | Market Perform | $50.00 | $25.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $37.00 | $30.00 |
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $20.00 | $15.00 |
| Anupam Rama | JP Morgan | Announces | Neutral | $24.00 | - |
| Gena Wang | Barclays | Lowers | Underweight | $10.00 | $18.00 |
| Andrew Tsai | Jefferies | Lowers | Buy | $35.00 | $40.00 |
| Yanan Zhu | Wells Fargo | Lowers | Overweight | $48.00 | $65.00 |
| Yigal Nochomovitz | Citigroup | Announces | Sell | $7.00 | - |
| Tazeen Ahmad | B of A Securities | Lowers | Underperform | $10.00 | $20.00 |
| Kostas Biliouris | BMO Capital | Lowers | Market Perform | $25.00 | $50.00 |
| Biren Amin | Piper Sandler | Lowers | Neutral | $11.00 | $18.00 |
| Gena Wang | Barclays | Lowers | Equal-Weight | $18.00 | $32.00 |
| Eliana Merle | UBS | Lowers | Neutral | $12.00 | $45.00 |
| Uy Ear | Mizuho | Lowers | Neutral | $14.00 | $40.00 |
| Biren Amin | Piper Sandler | Lowers | Neutral | $18.00 | $32.00 |
| Kostas Biliouris | BMO Capital | Lowers | Market Perform | $50.00 | $70.00 |
| Mani Foroohar | Leerink Swann | Lowers | Market Perform | $10.00 | $45.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $20.00 | $28.00 |
| Gil Blum | Needham | Maintains | Hold | $50.00 | $50.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Neutral | $20.00 | $28.00 |
| Hartaj Singh | Oppenheimer | Lowers | Outperform | $41.00 | $45.00 |
| Yanan Zhu | Wells Fargo | Lowers | Overweight | $65.00 | $75.00 |
| Gena Wang | Barclays | Raises | Overweight | $32.00 | $29.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $23.00 | $25.00 |
| Brian Skorney | Baird | Raises | Outperform | $35.00 | $30.00 |
| Gil Blum | Needham | Maintains | Buy | $50.00 | $50.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $28.00 | $30.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Lowers | Sell | $10.00 | $40.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $30.00 | $84.00 |
| Hartaj Singh | Oppenheimer | Lowers | Outperform | $45.00 | $123.00 |
| Uy Ear | Mizuho | Lowers | Outperform | $40.00 | $85.00 |
| David Hoang | Deutsche Bank | Lowers | Hold | $25.00 | $50.00 |
| Salveen Richter | Goldman Sachs | Announces | Neutral | $29.00 | - |
| Matthew Harrison | Morgan Stanley | Lowers | Equal-Weight | $40.00 | $113.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Sarepta Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sarepta Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Sarepta Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Sarepta Therapeutics: Delving into Financials
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Sarepta Therapeutics's remarkable performance in 3M is evident. As of 30 June, 2025, the company achieved an impressive revenue growth rate of 68.38%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sarepta Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 32.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 15.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sarepta Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.51% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Sarepta Therapeutics's debt-to-equity ratio is below the industry average at 1.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
